Skip to main content
Explore URMC

menu

Lymphoma (FL): Obinutuzumab With or Without PI3K-delta Inhibitor TGR-1202, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma

Research Question:
What are the good and bad effects of using TGR-1202 and lenalidomide in combination with the antibody, obinutuzumab?

Basic Study Information

Purpose:
During the study, you will get either obinutuzumab plus TGR-1202, obinutuzumab plus lenalidomide, or obinutuzumab plus the usual approach treatment for your cancer.

Location: Cancer Center
Study Web URL:  https://clinicaltrials.gov/ct2/show/NCT03269669?term=S1608&rank=1
Study Reference #: CLYM17097

Lead Researcher (Principal Investigator)

Lead Researcher: Paul Barr

Study Contact Information

Study Coordinator: Andrew Bui
Phone: (585) 276-4405
Email: Andrew_Bui@URMC.Rochester.edu

Additional Study Details

Return to Search